PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. Mar 8, 2004; 90(5): 941–943.
Published online Mar 2, 2004. doi:  10.1038/sj.bjc.6601626
PMCID: PMC2409637
Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels?
E S Schernhammer1,2* and K Schulmeister3
11Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
22Ludwig Boltzmann-Institute for Applied Cancer Research, KFJ-Spital, Vienna, Austria
33ARC Seibersdorf research, Health Physics Division, Seibersdorf A-2444, Austria
*Author for correspondence: eva.schernhammer/at/channing.harvard.edu
Received October 9, 2003; Revised December 3, 2003; Accepted December 5, 2003.
Keywords: melatonin, cancer, light exposure, night work
Light and melatonin
Light at night is an environmental exposure that has become integral to our lives. Before 1879, when the light-bulb was invented, humans were exposed to only insignificant amounts of low-intensity light at night from sources such as candles and petroleum lamps. Later on, paralleled by growing industrialisation, a need for longer days emerged, with electric light making it possible to push multifaceted working schedules further and further into the night. Today, exposure to light at night, both in the form of occupational exposure during night work and as a personal choice and lifestyle, is experienced by numerous night-active members of our societies. We, however, do not appear to be well adapted to bright nights: shift workers, for instance, reportedly suffer from a variety of health problems (Vener et al, 1989; Costa, 1997; Boggild and Knutsson, 1999). Previously, humans tended to conduct their daily activities according to the sun's cycle: rising at sunrise and going to bed at sunset. Such sleep rhythms appear not only to be more natural, but also to be essential for a variety of physiologic functions in humans, such as body temperature, excretion, and the production of hormones (Weitzman et al, 1981; Czeisler and Klerman, 1999). Melatonin, for example, follows a very distinct pattern of production, which is very closely linked to the individual's circadian rhythm, following light exposure: during the day, almost no melatonin is produced, whereas during the night, when it is dark, almost all melatonin is produced (Snyder et al, 1967). Environmental lighting powerfully alters physiologic release of melatonin, which typically peaks in the middle of the night (Zeitzer et al, 2000): a profound melatonin reduction was observed in humans after 2 weeks of intermittent nightly exposure to light (Zeitzer et al, 2000; Graham and Cook, 2001). While levels may recover during the periods of sleep, they will not recover to their maximal amount unless habits are kept constant, because any disruption of a natural circadian rhythm will diminish the ability to recover from that suppression.
Link between light at night and breast cancer risk through the oestrogen pathway
Past studies suggested that the excess breast cancer mortality seen in urban areas as well as the North East as compared to the South of the US could be due to differences in exposure to sunlight (Garland et al, 1990), perhaps mediated through the vitamin D pathway. However, based on a large body of experimental work in the 1960s and 70s, evidence grew that visible light, including artificial light, can acutely suppress melatonin. Thus, novel hypotheses were generated, proposing that the diminished function of the pineal gland might promote the development of breast cancer in humans. One of the initial theories supporting that a diminished function of the pineal gland might promote the development of cancer hypothesised that melatonin suppression may lead to an increase in levels of reproductive hormones, particularly oestradiol, thereby increasing the growth and proliferation of hormone-sensitive cells in the breast (Cohen et al, 1978; Stevens, 1987).
Observational studies have supported that theory, indicating that women in occupations that expose them to light at night do experience a higher risk of breast cancer, and that blind women, who do not have the ability to experience lower melatonin levels because of their supposed lack of receptivity to light, have a lower incidence of breast cancer (Schernhammer and Hankinson, 2003). Studies fairly consistently report meaningful increases in breast cancer risk among postmenopausal women exposed to shift work (Pukkala et al, 1995; Tynes et al, 1996; Davis et al, 2001; Hansen, 2001; Rafnsson et al, 2001; Schernhammer et al, 2001). Two retrospective studies of flight attendants with occupational exposure to light at night linked the employment time to an increased risk of breast cancer (Pukkala et al, 1995; Rafnsson et al, 2001). Two nationwide record linkage studies (Tynes et al, 1996; Hansen, 2001) and a retrospective case–control study (Davis et al, 2001) associated night work with an approximately 50% higher risk of breast cancer (Tynes et al, 1996; Hansen, 2001). Finally, the Nurses’ Health Study, the only prospective study published that evaluated the association, observed a positive association of extended periods of rotating night work and breast cancer risk (more than 30 years of rotating night work: RR=1.36; 95% CI=1.04–1.78) (Schernhammer et al, 2001). In this study, night work was defined as the total number of years during which the nurses had worked rotating night shifts with at least three nights per month, in addition to days and evenings in that month. During 10 years of follow-up, 2441 incident cases of breast cancer were documented among 78 562 women. A positive association between the number of years a woman had worked on rotating night shifts and breast cancer risk was observed (test for trend, P=0.02). Among postmenopausal women, the relative risk for breast cancer, controlling for all the major risk factors for breast cancer, was moderately increased after 1–14 and 15–29 years of rotating night shift work, and was further increased (RR 1.36; 95% CI 1.04–1.78) for those nurses who worked the night shift for 30 or more years, with similar risks for premenopausal women (RR 1.34; 95% CI 0.77–2.33). Thus, in sum, observational studies seem to support the hypothesis that night work increases the risk for breast cancer. This association may be mediated, at least in part, by the oestrogen pathway.
Light at night and other cancers
Only few previous observational studies have addressed the relationship between shift work and cancers, other than breast cancer. Early suggestions for an increased cancer risk related to shift work arose from two mortality studies that were conducted among male shift workers to assess the influence of shift work upon total and cause-specific mortality, with suggestions for an increased cancer mortality related to shift work. Tynes et al report an increased risk of colon (SIR 1.3; 95% CI 0.6–2.6) and rectum cancer (SIR 1.8; 95% CI 0.7–3.9) in their cohort of female radio and telegraph workers. Rafnsson and colleagues do not report the risks for colorectal cancer among the female Icelandic flight attendants, but describe an elevated risk for tumours of the lymphatic system.
In recent years, an overwhelming amount of research has been devoted to exploring the cancer-protective properties of the hormone melatonin. Today, many of the oncostatic properties of melatonin have been fairly well described (Vijayalaxmi et al, 2002), and evidence from experimental studies strongly suggests a link between melatonin and tumour suppression (Schernhammer and Hankinson, 2003). In vitro studies, although not entirely consistent (Panzer et al, 1998), give support to a reduction in the growth of malignant cells of the breast (Hill and Blask, 1988; Cos et al, 1996, 1998, 2002; Mediavilla et al, 1999) and other tumour sites (Sze et al, 1993; Ying et al, 1993; Petranka et al, 1999; Shiu et al, 1999; Kanishi et al, 2000) by both pharmacological and physiologic doses of melatonin. In rodent models, pinealectomy boosts tumour growth (Tamarkin et al, 1981), whereas exogenous melatonin administration exerts anti-initiating (Musatov et al, 1999) and oncostatic activity (Anisimov et al, 1997, 1999; Cini et al, 1998; Mocchegiani et al, 1999) in various chemically induced cancers. The most prominent mechanisms proposed to explain the oncostatic action of melatonin include its antimitotic and antioxidant activity (Brzezinski, 1997), and its potential modulation of cell-cycle length through control of the p53–p21 pathway (Mediavilla et al, 1999). Melatonin is believed to have antimitotic activity by its direct effect on hormone-dependent proliferation through interaction with nuclear receptors. Another explanation is that melatonin increases the expression of the tumour-suppressor gene p53. Cells lacking p53 have been shown to be genetically unstable and thus more prone to tumours.
In vitro studies do support not only an effect of melatonin on breast cancer (Hill and Blask, 1988; Cos et al, 1996, 1998, 2002; Mediavilla et al, 1999), but also on other tumours. In fact, to date, melatonin has been shown to be oncostatic for a variety of tumour cells in experimental carcinogenesis (Sze et al, 1993; Ying et al, 1993; Petranka et al, 1999; Shiu et al, 1999; Kanishi et al, 2000). Reports show that melatonin exhibits a growth-inhibitory effect on endometrial (Kanishi et al, 2000) and ovarian carcinoma cell lines (Petranka et al, 1999), Lewis lung carcinoma (Mocchegiani et al, 1999), prostate tumour cells (Laufer et al, 1999), and intestinal tumours (Anisimov et al, 1997, 2000a, 2000b), for example. Furthermore, today, several clinical trials confirm the potential of melatonin, either alone or in combination with standard therapy regimens, to generate a favourable response in the treatment of human cancers (Vijayalaxmi et al, 2002).
Given the evidence from experimental studies supporting the general oncostatic property of melatonin, we therefore speculate that exposure to light at night not only has an impact on breast cancer risk, but also may increase the risk of other cancers, primarily through the melatonin pathway. This has been posed previously (Kerenyi et al, 1990) without much further attention from the scientific community, but most recent evidence from observational studies supports such a link. The Nurses’ Health Study Cohort was used to explore the association between night work and colorectal cancer; 602 women were diagnosed with incident colorectal cancer during the 10 years of follow-up. In these analyses, women who worked 15 or more years on rotating night shifts were at a higher risk of colorectal cancer than were women who never worked rotating night shifts. The relative risks after adjustment for age, smoking, physical activity, and other colorectal cancer risk factors were 1.00 (0.84–1.19) for 1–14 years on rotating night shifts and 1.35 (1.03–1.77) for 15 or more years on rotating night shifts (test for trend, P=0.04).
On the basis of the observed effect of night work on colorectal cancer, which, contrary to breast cancer cannot be fully explained by variations in circulating oestrogen levels, taken together with consistent evidence from experimental studies, we believe that the effects of light exposure at night on cancer risk may be explained, at least in part, by the direct oncostatic mechanisms of melatonin. We propose that an increase in light exposure during the night decreases the amount of time available for melatonin production, which reduces the possible nonspecific oncostatic effect of the pineal gland, thus increasing the risk not only of breast cancer but also of other cancers. Although other aetiologic mechanisms, such as the loss of normal diurnal variation in cortisol (Spiegel and Sephton, 2002), may be involved in the influence of night work on cancer risk, we suggest that melatonin may be the primary culprit for this association. Future research should therefore evaluate the relationship of light exposure to the risk of not only breast but also other cancers, including cancer risks in men. There is also a need for research that addresses individual susceptibility and the question whether individuals with lower melatonin levels choose to do night work more often than do those with higher melatonin levels. First and foremost, however, associations between melatonin levels and cancer risk in humans need to be evaluated.
  • Anisimov VN, Kvetnoy IM, Chumakova NK, Kvetnaya TV, Molotkov AO, Pogudina NA, Popovich IG, Popuchiev VV, Zabezhinski MA, Bartsch H, Bartsch C. Melatonin and colon carcinogenesis. Exp Toxicol Pathol. 1999;51:47–52. [PubMed]
  • Anisimov VN, Popovich IG, Shtylik AV, Zabezhinski MA, Ben-Huh H, Gurevich P, Berman V, Tendler Y, Zusman I. Melatonin and colon carcinogenesis. III. Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by 1,2-dimethylhydrazine in rats. Exp Toxic Pathol. 2000a;52:71–76.
  • Anisimov VN, Popovich IG, Zabezhinski MA. Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis. 1997;18:1549–1553. [PubMed]
  • Anisimov VN, Zabezhinski MA, Popovich IG, Zaripova EA, Musatov SA, Andre V, Vigreux C, Godard T, Sichel F. Inhibitory effect of melatonin on 7, 12-dimethylbenz[a]anthracene-induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro. Cancer Lett. 2000b;156:199–205. [PubMed]
  • Boggild H, Knutsson A. Shift work, risk factors and cardiovascular disease. Scand J Work Environ Health. 1999;25:85–99. [PubMed]
  • Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186–195. [PubMed]
  • Cini G, Coronnello M, Mini E, Neri B. Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat. Cancer Lett. 1998;125:51–59. [PubMed]
  • Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet. 1978;2:814–816.
  • Cos S, Fernandez F, Sanchez-Barcelo EJ. Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci. 1996;58:2447–2453. [PubMed]
  • Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 1998;58:4383–4390. [PubMed]
  • Cos S, Mediavilla MD, Fernandez R, Gonzalez-Lamuno D, Sanchez-Barcelo EJ. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro. J Pineal Res. 2002;32:90–96. [PubMed]
  • Costa G. The problem: shiftwork. Chronobiol Int. 1997;14:89–98. [PubMed]
  • Czeisler CA, Klerman EB. Circadian and sleep-dependent regulation of hormone release in humans. Recent Prog Horm Res. 1999;54:97–130. [PubMed]
  • Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93:1557–1562. [PubMed]
  • Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med. 1990;19:614–622. [PubMed]
  • Graham C, Cook MR. Examination of the melatonin hypothesis in women exposed at night to EMF or bright light. Environ Health Perspect. 2001;109:501–507.
  • Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology. 2001;12:74–77. [PubMed]
  • Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res. 1988;48:6121–6126. [PubMed]
  • Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res. 2000;28:227–233. [PubMed]
  • Kerenyi NA, Pandula E, Feuer G. Why the incidence of cancer is increasing: the role of ‘light pollution’ Med Hypotheses. 1990;33:75–78. [PubMed]
  • Laufer GE, Matzkin H, Zisapel N. Melatonin receptors in PC3 human prostate tumor cells. J Pineal Res. 1999;26:211–220. [PubMed]
  • Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci. 1999;65:415–420. [PubMed]
  • Mocchegiani E, Perissin L, Santarelli L, Tibaldi A, Zorzet S, Rapozzi V, Giacconi R, Bulian D, Giraldi T. Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2. Int J Immunopharmacol. 1999;21:27–46. [PubMed]
  • Musatov SA, Anisimov VN, Andre V, Vigreux C, Godard T, Sichel F. Effects of melatonin on N-nitroso-N-methylurea-induced carcinogenesis in rats and mutagenesis in vitro (Ames test and COMET assay) Cancer Lett. 1999;138:37–44. [PubMed]
  • Panzer A, Lottering ML, Bianchi P, Glencross DK, Stark JH, Seegers JC. Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. Cancer Lett. 1998;122:17–23. [PubMed]
  • Petranka J, Baldwin WS, Bierman J, Jayadev S, Barrett JC, Murphy E. The oncostatic action of melatonin in an ovarian carcinoma cell line. Pineal Res. 1999;26:129–136.
  • Pukkala E, Auvinen H, Wahlberg G. Incidence of cancer among Finnish airline cabin attendants. Br Med J. 1995;311:649–652.
  • Rafnsson V, Tulinius H, Jonasson JG, Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland) Cancer Causes Control. 2001;12:95–101. [PubMed]
  • Schernhammer ES, Hankinson SE. Light at night: a novel risk factor for cancer in shift workers. Clin Occup Environ Med. 2003;3:263–278.
  • Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst. 2001;93:1563–1568. [PubMed]
  • Shiu SY, Li L, Xu JN, Pang CS, Wong JT, Pang SF. Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. Pineal Res. 1999;27:183–192.
  • Snyder SH, Axelrod J, Zweig M. Circadian rhythm in the serotonin content of the rat pineal gland: regulating factors. J Pharmacol Exp Ther. 1967;158:206–213. [PubMed]
  • Spiegel D, Sephton S. Re: Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2002;94:530.
  • Stevens RG. Electric power use and breast cancer: a hypothesis. Am J Epidemiol. 1987;125:556–561. [PubMed]
  • Sze SF, Ng TB, Liu WK. Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res. 1993;14:27–33. [PubMed]
  • Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res. 1981;41:4432–4436. [PubMed]
  • Tynes T, Hannevik M, Andersen A, Vistnes A, Haldorsen T. Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control. 1996;7:197–204. [PubMed]
  • Vener KJ, Szabo S, Moore JG. The effect of shift work on gastrointestinal (GI) function: a review. Chronobiologia. 1989;16:421–439. [PubMed]
  • Vijayalaxmi, Thomas CRJ, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002;20:2575–2601. [PubMed]
  • Weitzman ED, Czeisler CA, Zimmerman JC, Moore-Ede MC. Biological rhythms in man: relationship of sleep–wake, cortisol, growth hormone, and temperature during temporal isolation. Adv Biochem Psychopharmacol. 1981;28:475–499. [PubMed]
  • Ying SW, Niles LP, Crocker C. Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol. 1993;246:89–96. [PubMed]
  • Zeitzer JM, Dijk DJ, Kronauer R, Brown E, Czeisler C. Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol. 2000;526:695–702. [PubMed]
Articles from British Journal of Cancer are provided here courtesy of
Cancer Research UK